Barrington Research Lifts Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX) – Stock analysts at Barrington Research increased their FY2025 earnings per share (EPS) estimates for shares of Surmodics in a report issued on Thursday, November 7th. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of $0.21 for the year, up from their prior forecast of $0.19. The consensus estimate for Surmodics’ current full-year earnings is $0.16 per share. Barrington Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.17 EPS.

SRDX has been the subject of several other research reports. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research report on Thursday. StockNews.com initiated coverage on Surmodics in a research note on Thursday. They set a “hold” rating on the stock. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Surmodics has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Price Performance

Shares of NASDAQ:SRDX opened at $38.40 on Friday. The business has a fifty day moving average price of $38.60 and a 200-day moving average price of $38.60. Surmodics has a 1-year low of $25.17 and a 1-year high of $42.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its stake in Surmodics by 11.3% during the first quarter. Acadian Asset Management LLC now owns 408,779 shares of the company’s stock valued at $11,988,000 after buying an additional 41,617 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Surmodics by 5.0% during the 2nd quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock valued at $25,499,000 after acquiring an additional 28,990 shares during the last quarter. Gardner Lewis Asset Management L P purchased a new position in shares of Surmodics in the second quarter valued at $8,531,000. Sagefield Capital LP bought a new stake in Surmodics in the second quarter worth $2,350,000. Finally, Trium Capital LLP bought a new position in Surmodics during the second quarter valued at $1,406,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).